Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2021-08-10 Regulatory Filings
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1913 characters) and contains the header 'RNS Number : 2076I' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content itself is a brief announcement regarding a 'Price Monitoring Extension' for a security, which is a specific, non-financial regulatory market event update. This type of short, specific regulatory announcement that doesn't fit into the major financial reporting categories (like 10-K, ER, IR) is best classified as a general Regulatory Filing, which corresponds to the RNS code.
2021-08-10 English
Board Changes
Board/Management Information Classification · 1% confidence The document is an official announcement released via RNS (Regulatory News Service) on July 30, 2021. The primary subject matter, clearly stated in the title and body, is 'BOARD CHANGES'. It details the resignation of the CEO and two Non-Executive Directors (NEDs), the appointment of the Chairman as interim CEO, and the appointment of two new NEDs (Dr Sanjeev Pandya and Lisa Baderoon). This content directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2021-07-30 English
Board Changes
Board/Management Information Classification · 1% confidence The document is explicitly titled "BOARD CHANGES" and details the resignation of the CEO and two Non-Executive Directors, along with the appointment of a new CEO (the Chairman taking on the role temporarily), a new Senior independent NED, and a new NED. This content directly corresponds to the definition of Board/Management Information, which is classified as 'MANG'. The document is a formal announcement, not a general regulatory filing (RNS) or a report itself.
2021-07-30 English
Board Appointment
Board/Management Information Classification · 1% confidence The document is identified by the RNS Number header and explicitly states it is being provided by RNS, the news service of the London Stock Exchange. The content announces the 'BOARD APPOINTMENT' of Dr Tim Franklin as Chief Operating Officer to the Board of Directors, including details about his background and required AIM Rule disclosures. This type of announcement, concerning changes in senior management or the board, directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the core subject matter is management change, making MANG the most specific classification.
2021-07-16 English
BOARD APPOINTMENT
Board/Management Information Classification · 1% confidence The document is titled "BOARD APPOINTMENT" and explicitly announces the appointment of Dr. Tim Franklin to the Board of Directors of ImmuPharma PLC. This directly corresponds to the definition of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management. The classification code for this is MANG.
2021-07-16 English
2021 RESULT OF ANNUAL GENERAL MEETING -REPLACEMENT
AGM Information Classification · 1% confidence The document is an RNS announcement (RNS Number : 3507D) titled '2021 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED'. It explicitly details the results of shareholder votes on various resolutions presented at the Annual General Meeting (AGM), including percentages for 'For', 'Against', and 'Withheld'. This content directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). Although it relates to an AGM, the core content is the voting outcome tabulation, making DVA more specific than AGM-R (which usually covers presentations/materials). The document also mentions an amendment to a previous AGM result announcement, reinforcing the focus on meeting outcomes.
2021-06-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.